BINDING PROTEINS AND CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING GASP-I GRANULES AND USES THEREOF

Abstract

A method for detecting cells having granules expressing G protein coupled receptor-associated sorting protein 1 (GASP-1) or a fragment thereof is provided. The detection method may comprise: (a) contacting the cells with an effective amount of a binding protein, wherein the binding protein comprises an antigen binding fragment that specifically binds GASP-1; and (b) identifying cells having granules bound to the binding protein. The GASP-1 granules may be in the cytosol or on the surface of the cells. Also provided are methods for producing T-cells comprising a chimeric antigen receptor, anti-GASP-1 antibody or a bi-specific binding protein. Further provided are methods for treating GASP-1-mediated to disease or inactivating exosomes, microvesicles or oncosomes.

Claims

1. A method for detecting cells having granules expressing G protein coupled receptor-associated sorting protein 1 (GASP-1) or a fragment thereof, comprising: (a) contacting the cells with an effective amount of a binding protein, wherein the binding protein comprises an antigen binding fragment that specifically binds GASP-1; and (b) identifying cells having granules bound to the binding protein, wherein the identified cells are cells having GASP-1 granules.

2. The method of claim 1, wherein the GASP-1 granules in the cells have a diameter in the range from 0.1 to 5.0 ?m.

3. The method of claim 1, wherein the average number of the GASP-1 granules in the cells is in the range from 20 to 150 per cell.

4. The method of claim 1, wherein the GASP-1 granules are in the cytosol or on the surface of the cells.

5. The method of claim 1, wherein the cells are in a tumor.

6. The method of claim 5, wherein the tumor is a solid tumor or hematological tumor.

7. The method of claim 1, wherein the cells are cancer cells.

8. The method of claim 1, wherein the cells are in a subject having cancer.

9. The method of claim 8, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, endometrial carcinoma, esophagus squamous cell carcinoma, glioma, head cancer, hepatocellular carcinoma, infiltrating ductal breast carcinoma, larynx cancer, lung cancer, melanoma, mucinous cystadenocarcinoma of ovary, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small bowel malignant stromal tumor and stomach adenocarcinoma.

10. The method of claim 9, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, glioblastoma, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer and prostate cancer.

11. The method of claim 9 or 10, wherein the breast cancer is high grade ductal carcinoma in situ (DCIS) breast cancer or triple negative breast cancer.

12. The method of claim 9 or 10, wherein the lung cancer is non-small cell lung cancer (NSCLC).

13. The method of claim 8, wherein the subject has received a cancer treatment.

14. The method of claim 1, further comprising detecting a cancer biomarker in the cells.

15. The method of claim 14, wherein the cancer biomarker is selected from the group consisting of CA125, CA19-9, CA15-3, CA27.29, AFP, BRCA1/BRCA2, EGFR, HER-2, KIT, VEGF, KRAS, ALK, PSA, HE4, CYFRA 21-1, NSE, PD-L1, TIMP-1, TIMP-2, HGF, OPN, MSLN, MMP2 and CEA.

16. The method of claim 1, wherein the binding protein is a humanized antibody or a chimeric antigen receptor (CAR).

17. A binding protein comprising an anti-GASP-1 single-chain variable fragment (anti-GASP-1 scFv).

18. The binding protein of claim 17, wherein the anti-GASP-1 scFv comprises a variable heavy (VH) chain and a variable light (VL) chain.

19. The binding protein of claim 18, wherein the VH chain comprises an amino acid sequence of SEQ ID NO: 1.

20. The binding protein of claim 17, wherein the VH chain comprises a first complementarity-determining region 1 (VHCDR1) consisting of the amino acid sequence of SEQ ID NO: 2, a second complementarity-determining region 2 (VHCDR2) consisting of the amino acid sequence of SEQ ID NO: 3, a third complementarity-determining region 3 consisting of the amino acid sequence of SEQ ID NO: 4 (VCCDR3), or a combination thereof.

21. The binding protein of claim 17, wherein the VL chain comprises SEQ ID NO: 9 or 17.

22. The binding protein of claim 17, wherein the VL chain comprises a first complementarity-determining region (VL1CDR1) consisting of the amino acid sequence of SEQ ID NO: 10 or 18, a second complementarity-determining region (VL1CDR2) consisting of the amino acid sequence of SEQ ID NO: 11, and a third complementarity-determining region (VL1CDR3) consisting of the amino acid sequence of SEQ ID NO: 12.

23. The binding protein of claim 17, wherein the VH chain is connected to the VL chain with a linker.

24. The binding protein of claim 17, wherein the linker comprises the amino acid sequence of SEQ ID NO: 21.

25. The binding protein of claim 17, wherein the anti-GASP-1 scFv binds specifically an immunodominant epitope of GASP-1 and the immunodominant epitope comprises the amino acid sequence of SEQ ID NO: 22.

26. The binding protein of claim 17, wherein the binding protein is an antibody selected from the group consisting of a recombinant monoclonal antibody, a polyclonal antibody, a humanized antibody and an antigen binding fragment thereof.

27. The binding protein of claim 26, wherein the binding protein is a humanized antibody.

28. The binding protein of claim 17, wherein the binding protein is a chimeric antigen receptor (CAR) comprising the anti-GASP-1 scFv.

29. The binding protein of claim 28, wherein the anti-GASP-1 scFv comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 36 and 43.

30. The binding protein of claim 17, comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4, 9-12 and 17-18.

31. The binding protein of claim 17, wherein the binding protein is conjugated with a chemotherapeutic agent.

32. The binding protein of claim 31, wherein the chemotherapeutic agent is selected from the group consisting of Anastrozole, Exemestane, Letrozole, Palbociclib, Ribociclib, Neratinib, Abemaciclib, Olaparib, Regorafenib, Tretinoin, axicabtagene ciloleucel, Dasatinib, Nilotinib, Bosutinib, Ibrutinib, Idelalisib, Venetoclax, Ponatinib, Midostaurin, Enasidenib, Tisagenlecleucel, Ivosideni, Duvelisib, Imatinib, Gefitinib, Erlotinib, Lapatinib, Sorafenib, Abiraterone, Critozinib, Vemurafenib, radioactive isotopes such as .sup.111In and .sup.90Y, toxins such as auristatins, maytansinoids, doxorubicin, taxols, cisplatin, vinblastine, calicheamicin, and Pseudomonas exotoxin A.

33. A method for producing T cells comprising a chimeric antigen receptor (CAR-T cells), comprising: (a) introducing into T cells a gene encoding a CAR comprising an anti-GASP-1 single-chain variable fragment (anti-GASP-1 scFv), (b) expressing the anti-GASP-1 scFv by the T cells, and (c) isolating T cells expressing the anti-GASP-1 scFv.

34. The method of claim 33, wherein the anti-GASP-1 scFv comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 36 and 43.

35. A method for producing an anti-GASP-1 antibody comprising immunizing a host with a GASP-1 peptide as an immunogen.

36. The method of claim 35, wherein the GASP-1 peptide comprises the amino acid sequence of SEQ ID NO: 22.

37. A method for producing a bi-specific binding protein, comprising combining the binding protein of claim 16 with an additional humanized antibody, whereby a bi-specific binding protein is produced with better immunotherapy specificity and/or efficacy than the humanized antibody.

38. The method of claim 37, wherein the binding protein is a humanized GASP-1 antibody or a chimeric antigen receptor (CAR).

39. The method of claim 37 or 38, wherein the additional humanized antibody is selected from the group consisting of Rituximab, Alemtuzumab, Adalimumab, Efalizumab, Cetuximab, Bevacizumab, Natalizumab, Panitumumab, Ranibizumab, Ipilimumab, Belimumab, Obinutuzumab, Pertuzumab, Vedolizumab, Ramucirumab, Evolocumab, Pembrolizumab, Nivolumab, Atezolizumab, Reslizumab, Necitumumab, Trastuzumab, Pertuzumab, Ofatumumab, Durvalumab, Bortezomib, Elotuzumab, Avelumab, Cemiplimab, and Olaratumab.

40. A bi-specific binding protein prepared according to the method of any one of claims 37-39.

41. A pharmaceutical composition comprising the binding protein of any one of claims 17-32 or a bi-specific binding protein of claim 40, and a pharmaceutically acceptable carrier.

42. A method for treating a GASP-1-mediated disease or disorder in a subject in need thereof, comprising administering an effective amount of the pharmaceutical composition of claim 41 to the subject.

43. The method of claim 42, wherein the GASP-1-mediated disease or disorder is a tumor.

44. The method of claim 43, wherein the tumor is a solid tumor.

45. The method of claim 43, wherein the tumor is a hematological tumor.

46. The method of claim 42, wherein the GASP-1-mediated disease or disorder is cancer.

47. The method of claim 42, wherein the subject has received a treatment of cancer.

48. The method of any one of claims 42-47, wherein the GASP-1 are expressed in granules in cells of the subject.

49. The method of claim 48, wherein the granules are in the cytosol or on the surface of the cells.

50. A method for inhibiting growth of cells expressing GASP-1, comprising administering an effective amount of the pharmaceutical composition of claim 41 to the cells.

51. The method of claim 50, wherein the cells are cancer cells.

52. The method of claim 50, wherein the cells are in a patient having cancer.

53. A method for inactivating exosomes, microvesicles, or oncosomes expressing GASP-1, comprising administering an effective amount of the pharmaceutical composition of claim 41 to the exosomes, microvesicles, or oncosomes.

54. The method of claim 53, wherein the exosomes, microvesicles, or oncosomes are in a subject having cancer.

55. The method of claim 54, wherein the exosomes, microvesicles, or oncosomes are in blood circulation of the subject.

56. The method of claim 46, 52 or 54, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, endometrial carcinoma, esophagus squamous cell carcinoma, glioma, head cancer, hepatocellular carcinoma, infiltrating ductal breast carcinoma, larynx cancer, lung cancer, melanoma, mucinous cystadenocarcinoma of ovary, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small bowel malignant stromal tumor and stomach adenocarcinoma.

57. The method of claim 46, 52 or 54, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, glioblastoma, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer and prostate cancer.

58. The method of claim 56 or 57, wherein the breast cancer is high grade ductal carcinoma in situ (DCIS) breast cancer or triple negative breast cancer.

59. The method of claim 56 or 57, wherein the lung cancer is non-small cell lung cancer (NSCLC).

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0031] FIG. 1 shows extracellular oncosomes released from prostate cancer cells via membrane blebs protruding from cell membrane (right panel) but not from normal prostate cells (left panel).

[0032] FIG. 2 shows accumulation of GASP-1 granules of different sizes in the cytosol of high grade DCIS breast cancer cells (right panel) but not normal breast cells (left panel).

[0033] FIG. 3 shows numerous GASP-1 granules attached to the cell membrane or membrane fragments of high grade DCIS breast cancer cells.

[0034] FIG. 4 shows GASP-1 granules of different sizes on the cell membrane of triple negative breast cancer cells.

[0035] FIG. 5 shows accumulation of GASP-1 granules of different sizes in the cytosol of non-small cell lung cancer (NSCLC) cells (right panel) but not normal lung cells (left panel).

[0036] FIG. 6 shows accumulation of GASP-1 granules in the cytosol and on the cell membrane of glioblastoma cells (right panel) but not in normal brain cells (left panel).

[0037] FIG. 7 shows PCR products using VL specific primer (lane 1) or VH specific primer (lane 2). Lane M: 2000 DNA Marker, from top to bottom: 2000, 1000, 750, 500, 250, 100 bp, respectively.

[0038] FIG. 8 shows a schematic diagram of scFv1-Fc or scFv2-Fc expression vector of 4911 bp, including a signal sequence, a variable light chain (VL), a linker, a variable heavy chain (VH) and human IgG1 Fc (HIgG1-Fc).

[0039] FIG. 9 shows flow cytometric analysis (FACS) of PC3 cells stained with scFv1-Fc (right panel) or scFv2-Fc (left panel) as a primary antibody, and PE-anti-Human IgG Fc antibody as a secondary antibody.

[0040] FIG. 10 shows flow cytometric analysis (FACS) of A549 lung cancer cells (left pane) or SKOV3 ovarian cancer cells (right panel) stained with a GASP-1 monoclonal antibody as a primary antibody and an Alexa Fluor-A-anti-Human IgG Fc antibody as a secondary antibody.

[0041] FIG. 11 shows a schematic diagram of a chimeric antigen receptor (CAR) Lenti-EF1a-scFv1-CD28-CD3z-T2A-EGFRt of 10,228 bp.

[0042] FIG. 12 shows 34.9% of the T cells are CAR-positive.

[0043] FIG. 13 shows release of IFN-? (left panel) and IL-2 (right panel) by cancer cells upon exposure to CAR-10217-SIA-CAR-T cells.

DETAILED DESCRIPTION OF THE INVENTION

[0044] The present invention provides a binding protein comprising an anti-G protein coupled receptor-associated sorting protein 1 (GASP-1) single-chain variable fragment (scFv) and the uses of the anti-GASP-1 scFv for detecting cells expressing GASP-1 or a fragment thereof, for example, in or on the surface of granules in the cells, and for producing antibodies or T cells comprising a chimeric antigen receptor (CAR-T) for targeting GASP-1 expressing cancer cells. The invention is based on the inventors' surprising discovery of anti-GASP-1 single-chain variable fragments (scFv) as well as granules highly enriched with GASP-1 (GASP-1 granules). The GASP-1 granules are of different sizes, ranging from powdery granules, fine granules, to coarse granules whose surfaces are not smooth. The size of coarse granules may be about several hundred times that of the powdery granules. GASP-1 granules have been found widely distributed inside or on cell membrane of cancer cells, for example, underneath the cell membrane, in the cytosol, clustered around nucleus or inside the nucleus. The GASP-1 granules of various sizes have been found in cells from breast, triple negative, prostate, lung, liver, pancreatic, ovarian, glioblastoma, bladder, melanoma, or colon cancer.

[0045] The inventors have also surprisingly discovered that as cancer progresses, the GASP-1 granules may increase in both numbers and sizes. At an early stage of cancer, the GASP-1 granules may be predominantly of powdery to fine granules. At a late stage of highly invasive and aggressive cancer such as triple negative breast cancer (TNBC) and glioblastoma, GASP-1 granules may be primarily coarse GASP-1 granules.

[0046] In normal cells, GASP-1 may be only minimally expressed or not expressed in the cytosol and, if present, may be in a powdery form. The GASP-1 granules may be minimally present in the cytosol of normal cells but not present on cell membrane. The GASP-1 granules may be present in nuclei of some normal cells. The surprising discovery of the presence of the GASP-1 granules only on the surface of cancer cells but not normal cells provides a first example of a tumor-specific antigen (TSA). This discovery makes GASP-1 an ideal target for cancer immunotherapies using, for example, either CAR-T cells or a humanized monoclonal antibody containing a GASP-1 scFv sequence because targeting the GASP-1 granules for cancer treatment would have minimum side effects on normal cells.

[0047] The terms granules expressing G protein coupled receptor-associated sorting protein 1 (GASP-1) and GASP-1 granules are used herein interchangeably and refer to granules containing GASP-1 or a fragment thereof. Depending upon their sizes, there are three forms of GASP-1 granules: powdery, fine and coarse granules.

[0048] The term powdery GASP-1 granules as used herein refers to GASP-1 granules having a diameter in the range from 0.1 to 0.4 ?m. The term fine GASP-1 granules as used herein refers to GASP-1 granules having a diameter in the range of 0.4-1.0 ?m. The term coarse GASP-1 granules as used herein refers to GASP-1 granules having a diameter in the range of 1.0-5.0 ?m. The GASP-1 coarse granules are larger in diameter than the extracellular microvesicles. The GASP-1 granules may be in the cytosol or on the surface of the cells. The GASP-1 granules may be endosomes.

[0049] The terms single-chain Fv and scFv are used herein interchangeably and refer to a single chain peptide comprising a VH chain and a VL chain of an antibody against an antigen. For example, an anti-GASP-1 scFv refers to a single peptide comprising a VH chain and a VL chain of an anti-GASP-1 antibody. The scFv may further comprise a polypeptide linker between the VH and VL chains, enabling the scFv to form a desired structure for binding the antigen. Where the antibody is a humanized antibody, the single-chain peptide comprising the VH and VL chains of the antibody is a human single-chain Fv or hscFv.

[0050] The term microvesicles as used herein refers to extracellular vesicles (EV) formed by cell membrane and released from cell membrane surface of cells, for example, cancer cells. The microvesicles have a diameter of 0.1-1 ?m. The microvesicles are present in biological fluids such as blood, saliva, urine, and cerebrospinal fluid. The microvesicles may express GASP-1.

[0051] The term exosomes as used herein refers to extracellular vesicles (EV) originating from multivesicular bodies (MVB) of the late endocytic pathway and are released by fusion with cell membrane. The exosomes have a diameter of 30-100 nm. The exosomes are present in biological fluids such as blood, saliva, urine, and cerebrospinal fluid. The exosomes may express GASP-1.

[0052] The term oncosomes as used herein refers to extracellular vesicles (EV) formed by cell membrane and released from cell membrane surface of cells, for example, cancer cells. The oncosomes have a diameter of 1-10 ?m. The oncosomes are present in biological fluids such as blood, saliva, urine, and cerebrospinal fluid. The oncosomes may express GASP-1.

[0053] The term an effective amount as used herein refers to an amount of a pharmaceutical composition comprising a binding protein or a bi-specific binding protein required to achieve a stated goal (e.g., detecting cells having GASP-1 granules, treating a GASP-1-mediated disease or disorder in a subject in need thereof, inhibiting growth of cells expressing GASP-1, and inactivating exosomes, microvesicles or oncosomes). The effective amount of the pharmaceutical composition may vary depending upon the stated goals and the physical characteristics of the composition.

[0054] A method for detecting cells having granules expressing G protein coupled receptor-associated sorting protein 1 (GASP-1) or a fragment thereof is provided. The detection method comprises contacting the cells with an effective amount of a binding protein, and identifying cells having granules bound to the binding protein. The binding protein comprises an antigen binding fragment that specifically binds GASP-1. The identified cells are cells having GASP-1 granules.

[0055] According to the detection method, the GASP-1 granules may be in the cytosol or on the surface of the cells. In one embodiment, the GASP-1 granules may be in the cytosol of the cells. In another embodiment, the GASP-1 granules are on the surface of the cells. In yet another embodiment, the GASP-1 granules may not be in the nuclei of the cells.

[0056] According to the detection method, the number of the GASP-1 granules in the cells may vary. There may be about 10-1,000, 20-500, or 20-200 GASP-1 granules per cell. The average number of the GASP-1 granules in the cells is in the range from 20 to 150. The GASP-1 granules may be of different sizes, ranging from powdery granules, fine granules, to coarse granules. The coarse GASP-1 granules may be at least 10, 50, 100 or 500 times larger than the powdery granules in the same cell. The GASP-1 granules may have a diameter in the range of about 0.1-10, 0.1-0.4, 0.4-1.0, 1.0-5.0, 0.1-1.0, 0.1-5.0, 0.4-5.0, 0.2-10, 0.2-3.0, 0.2-5.0, 0.5-1.0 or 0.5-5.0 ?m. In one embodiment, the GASP-1 granules have a diameter in the range from 0.2 to 3.0 ?m. We have discovered that as cancer progresses, more coarse GASP-1 granules are found which could either be due to maturation of powdery (and/or fine granules) or to aggregation of these GASP-1 granules. In one embodiment, at least 30%, 40%, 50%, 60%, 70%, 80% or 90% of the GASP-1 granules may be coarse GASP-1 granules in cancer cells. At least 30%, 40%, 50%, 60%, 70%, 80% or 90% of the GASP-1 granules may be coarse GASP-1 granules in cells from cancers that are more aggressive, for example, high grade DCIS, triple negative breast cancer and glioblastoma. The coarse GASP-1 granules may be clustering around nuclear membrane and/or on cell membrane.

[0057] According to the detection method, the cells having GASP-1 granules may be in a tumor. The tumor may be a solid tumor or hematological tumor. The tumor may be in a subject. The subject may have cancer. The cancer may be selected from the group consisting of bladder cancer, breast cancer, colon cancer, endometrial carcinoma, esophagus squamous cell carcinoma, glioma, head cancer, hepatocellular carcinoma, infiltrating ductal breast carcinoma, larynx cancer, lung cancer, melanoma, mucinous cystadenocarcinoma of ovary, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small bowel malignant stromal tumor and stomach adenocarcinoma. For example, the cancer may be bladder cancer, breast cancer, colon cancer, glioblastoma, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer or prostate cancer. The breast cancer may be high grade ductal carcinoma in situ (DCIS) breast cancer or triple negative breast cancer. The lung cancer may be non-small cell lung cancer (NSCLC). The subject may have received a cancer treatment.

[0058] According to the detection method, the cells having GASP-1 granules may be cancer cells. The cells may be in a subject. The subject may have cancer. The cancer may be selected from the group consisting of bladder cancer, breast cancer, colon cancer, endometrial carcinoma, esophagus squamous cell carcinoma, glioma, head cancer, hepatocellular carcinoma, infiltrating ductal breast carcinoma, larynx cancer, lung cancer, melanoma, mucinous cystadenocarcinoma of ovary, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small bowel malignant stromal tumor and stomach adenocarcinoma. For example, the cancer may be bladder cancer, breast cancer, colon cancer, glioblastoma, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer or prostate cancer. The breast cancer may be high grade ductal carcinoma in situ (DCIS) breast cancer or triple negative breast cancer. The lung cancer may be non-small cell lung cancer (NSCLC). The subject may have received a cancer treatment.

[0059] The detection method may further comprise detecting a cancer biomarker in the cells having GASP-1 granules or GASP-1 or a fragment thereof. The cancer biomarker may be any suitable biomarker for bladder cancer, breast cancer, colon cancer, endometrial carcinoma, esophagus squamous cell carcinoma, glioma, head cancer, hepatocellular carcinoma, infiltrating ductal breast carcinoma, larynx cancer, lung cancer, melanoma, mucinous cystadenocarcinoma of ovary, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small bowel malignant stromal tumor or stomach adenocarcinoma. For example, the cancer may be bladder cancer, breast cancer, colon cancer, glioblastoma, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer or prostate cancer. The breast cancer may be high grade ductal carcinoma in situ (DCIS) breast cancer or triple negative breast cancer. The lung cancer may be non-small cell lung cancer (NSCLC). Exemplary cancer biomarkers include CA125, CA19-9, CA15-3, CA27.29, AFP, BRCA1/BRCA2, EGFR, HER-2, KIT, VEGF, KRAS, ALK, PSA, HE4, CYFRA 21-1, NSE, PD-L1, TIMP-1, TIMP-2, HGF, OPN, MSLN, MMP2 and CEA.

[0060] According to the detection method, the binding protein may comprise an anti-GASP-1 single-chain variable fragment (anti-GASP-1 scFv). The binding protein may be an anti-GASP-1 antibody or a chimeric antigen receptor (CAR). The anti-GASP-1 antibody is an antibody capable of binding to GASP-1 or its fragment, for example, a GAPS-1 peptide of EEASPEAVAGVGFESK (SEQ ID NO: 22). The anti-GASP-1 antibody may be a recombinant antibody or an antigen-binding fragment thereof. The antibody may be a monoclonal antibody, a polyclonal antibody or a humanized antibody.

[0061] A binding protein comprising an anti-GASP-1 single-chain variable fragment (anti-GASP-1 scFv) is also provided. The anti-GASP-1 scFv comprises a variable heavy (VH) chain and a variable light (VL) chain. The binding protein may be an antibody or a chimeric antigen receptor (CAR).

[0062] The VH chain of the anti-GASP-1 scFv may comprise the amino acid sequence of SEQ ID NO: 1. The VH chain may consist of the amino acid sequence of SEQ ID NO: 1. The VH chain may comprise a first complementarity-determining region 1 (VHCDR1), a second complementarity-determining region 2 (VHCDR2) and a third complementarity-determining region 3 (VHCDR3). The VHCDR1 may comprise the amino acid sequence of SEQ ID NO: 2. The VHCDR1 may consist of the amino acid sequence of SEQ ID NO: 2. The VHCDR2 may comprise the amino acid sequence of SEQ ID NO: 3. The VHCDR2 may consist of the amino acid sequence of SEQ ID NO: 3. The VHCDR3 may comprise the amino acid sequence of SEQ ID NO: 4. The VHCDR3 may consist of the amino acid sequence of SEQ ID NO: 4. The VHCDR1 may be encoded by a nucleotide sequence comprising SEQ ID NO: 6. The VHCDR1 may be encoded by the nucleotide sequence of SEQ ID NO: 6. The VHCDR2 may be encoded by a nucleotide sequence comprising SEQ ID No: 7. The VHCDR2 may be encoded by the nucleotide sequence of SEQ ID No: 7. The VHCDR3 may be encoded by a nucleotide sequence comprising SEQ ID NO: 8. The VHCDR3 may be encoded by the nucleotide sequence of SEQ ID NO: 8.

[0063] The VL chain of the anti-GASP-1 scFv may comprise the amino acid sequence of SEQ ID NO: 9. The VL chain may consist of the amino acid sequence of SEQ ID NO: 9. The VL chain may comprise a first complementarity-determining region 1 (VLCDR1), a second complementarity-determining region 2 (VLCDR2) and a third complementarity-determining region 3 (VLCDR3). The VLCDR1 may comprise the amino acid sequence of SEQ ID NO: 10. The VLCDR1 may consist of the amino acid sequence of SEQ ID NO: 10. The VL1CDR2 may comprise the amino acid sequence of SEQ ID NO: 11. The VL1CDR2 may consist of the amino acid sequence of SEQ ID NO: 11. The VL1CDR3 may comprise the amino acid sequence of SEQ ID NO: 12. The VL1CDR3 may consist of the amino acid sequence of SEQ ID NO: 12.

[0064] The VL chain of the anti-GASP-1 scFv may comprise the amino acid sequence of SEQ ID NO: 17. The VL chain may consist of the amino acid sequence of SEQ ID NO: 17. The VL chain may comprise a first complementarity-determining region 1 (VLCDR1), a second complementarity-determining region 2 (VLCDR2) and a third complementarity-determining region 3 (VLCDR3). The VLCDR1 may comprise an amino acid sequence of SEQ ID NO: 18. The VLCDR1 may consist of the amino acid sequence of SEQ ID NO: 18. The VL1CDR2 may comprise the amino acid sequence of SEQ ID NO: 11. The VL1CDR2 may consist of the amino acid sequence of SEQ ID NO: 11. The VL1CDR3 may comprise the amino acid sequence of SEQ ID NO: 12. The VL1CDR3 may consist of the amino acid sequence of SEQ ID NO: 12.

[0065] The anti-GASP-1 scFv may comprise a variable heavy (VH) chain encoded by the nucleotide sequence of SEQ ID NO: 5 and a variable light (VL) chain encoded by the nucleotide sequence of SEQ ID NO: 13. The VH chain may be connected to the VL chain with a linker consisting of the amino acid sequence of SEQ ID NO: 21. The anti-GASP-1 scFv may be an antibody selected against an immunodominant epitope of GASP-1 consisting of the amino acid sequence of SEQ ID NO: 22.

[0066] The anti-GASP-1 scFv may comprise a variable heavy (VH) chain encoded by the nucleotide sequence of SEQ ID NO: 5 and a variable light (VL) chain encoded by the nucleotide sequence of SEQ ID NO: 19. The VH chain may be connected to the VL chain with a linker consisting of the amino acid sequence of SEQ ID NO: 21. The anti-GASP-1 scFv may be an antibody selected against an immunodominant epitope of GASP-1 consisting of the amino acid sequence of SEQ ID NO: 22.

[0067] The anti-GASP-1 scFv may comprise a variable heavy (VH) chain consisting of the amino acid sequence of SEQ ID NO: 1, and a variable light (VL) chain consisting of the amino acid sequence of SEQ ID NO: 9. The VH chain may be connected to the VL chain with a linker consisting of the amino acid sequence of SEQ ID NO: 21. The anti-GASP-1 scFv may be selected against an immunodominant epitope of GASP-1 consisting of the amino acid sequence of SEQ ID NO: 22.

[0068] The anti-GASP-1 scFv may comprise a variable heavy (VH) chain consisting of the amino acid sequence of SEQ ID NO: 1, and a variable light (VL) chain consisting of the amino acid sequence of SEQ ID NO: 17. The VH chain may be connected to the VL chain with a linker consisting of the amino acid sequence of SEQ ID NO: 21. The anti-GASP-1 scFv may be selected against an immunodominant epitope of GASP-1 consisting of the amino acid sequence of SEQ ID NO: 22.

[0069] The VH chain of the anti-GASP-1 antibody or scFv may comprise a CDR1 consisting of the amino acid sequence of SEQ ID NO: 2, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 3, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 4.

[0070] The VH chain of the anti-GASP-1 antibody or scFv may comprise a CDR1 encoded by the nucleotide sequence of SEQ ID NO: 6, a VHCDR2 encoded by the nucleotide sequence of SEQ ID No: 7, and a VHCDR3 encoded by the nucleotide sequence of SEQ ID NO: 8.

[0071] The VL chain of the anti-GASP-1 scFv may comprise a CDR1 consisting of the amino acid sequence of SEQ ID NO: 10, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 11, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 12.

[0072] The VL chain of the anti-GASP-1 scFv may comprise a CDR1 encoded by the nucleotide sequence of SEQ ID NO: 14, a CDR2 encoded by the nucleotide sequence of SEQ ID NO: 15, and a CDR3 encoded by the nucleotide sequence of SEQ ID NO: 16.

[0073] The VL chain of the anti-GASP-1 scFv may comprise a CDR1 consisting of the amino acid sequence of SEQ ID NO: 18, a CDR2 consisting of the amino acid sequence of SEQ ID NO: 11, and a CDR3 consisting of the amino acid sequence of SEQ ID NO: 12.

[0074] The VL chain of the anti-GASP-1 scFv may comprise a CDR1 encoded by the nucleotide sequence of SEQ ID NO: 20, a CDR2 encoded by the nucleotide sequence of SEQ ID NO: 15, and a CDR3 encoded by the nucleotide sequence of SEQ ID NO: 16.

[0075] In the binding protein, the VH chain may be connected to the VL chain with a linker.

[0076] The linker may comprise the amino acid sequence of SEQ ID NO: 21. The linker may consist of the amino acid sequence of SEQ ID NO: 21.

[0077] The anti-GASP-1 scFv may bind specifically an immunodominant epitope of GASP-1. The immunodominant epitope may comprise the amino acid sequence of SEQ ID NO: 22. The immunodominant epitope may consist of the amino acid sequence of SEQ ID NO: 22.

[0078] The binding protein may be an antibody selected from the group consisting of a recombinant monoclonal antibody, a polyclonal antibody, a humanized antibody and an antigen binding fragment thereof. In one embodiment, the binding protein may be a humanized antibody.

[0079] The binding protein may be an anti-GASP-1 antibody, may be an antibody capable of binding to GASP-1 or its fragment, for example, a GASP-1 peptide of EEASPEAVAGVGFESK (SEQ ID NO: 22). The anti-GASP-1 antibody may be a recombinant antibody or an antigen-binding fragment thereof. The antibody may be a monoclonal antibody, a polyclonal antibody or a humanized antibody.

[0080] The binding protein may be a chimeric antigen receptor (CAR), comprising the anti-GASP-1 scFv. The anti-GASP-1 scFv may comprise the amino acid sequence comprising SEQ ID NO: 36. The anti-GASP-1 scFv may consist of the amino acid sequence of SEQ ID NO: 36. The anti-GASP-1 scFv may comprise the amino acid sequence comprising SEQ ID NO: 43. The anti-GASP-1 scFv may consist of the amino acid sequence of SEQ ID NO: 43.

[0081] The binding protein may comprise at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4, 9-12 and 17-18. The binding protein may comprise amino acid sequences of SEQ ID NOs: 1 and 9. The binding protein may comprise amino acid sequences of SEQ ID NOs: 1 and 17. The binding protein may comprise amino acid sequences of SEQ ID NOs: 2-4. The binding protein may comprise amino acid sequences of SEQ ID NOs: 10-12. The binding protein may comprise amino acid sequences of SEQ ID NOs: 11, 12 and 18. The binding protein may comprise amino acid sequences of SEQ ID NOs: 1 and 10-12. The binding protein may comprise amino acid sequences of SEQ ID NOs: 1, 11, 12 and 18. The binding protein may comprise amino acid sequences of SEQ ID NOs: 2-4 and 9. The binding protein may comprise amino acid sequences of SEQ ID NOs: 2-4 and 17.

[0082] The binding protein may be conjugated with a chemotherapeutic agent. The chemotherapeutic agent may be selected from the group consisting of Anastrozole, Exemestane, Letrozole, Palbociclib, Ribociclib, Neratinib, Abemaciclib, Olaparib, Regorafenib, Tretinoin, axicabtagene ciloleucel, Dasatinib, Nilotinib, Bosutinib, Ibrutinib, Idelalisib, Venetoclax, Ponatinib, Midostaurin, Enasidenib, Tisagenlecleucel, Ivosideni, Duvelisib, Imatinib, Gefitinib, Erlotinib, Lapatinib, Sorafenib, Abiraterone, Critozinib, Vemurafenib, radioactive isotopes such as .sup.111In and .sup.90Y, toxins such as auristatins, maytansinoids, doxorubicin, taxols, cisplatin, vinblastine, calicheamicin, and Pseudomonas exotoxin A.

[0083] A method for producing T cells comprising a chimeric antigen receptor (CAR-T cells) is provided. The CAR-T cell production method comprises introducing into T cells a gene encoding a CAR. The CAR comprises the anti-GASP-1 single-chain variable fragment (anti-GASP-1 scFv) of the present invention. The CAR production method further comprises expressing the anti-GASP-1 scFv by the T cells and isolating T cells expressing the anti-GASP-1 scFv.

[0084] According to the CAR-T cell production method, the anti-GASP-1 scFv may comprise the amino acid sequence of SEQ ID NO: 36. The anti-GASP-1 scFv may consist of the amino acid sequence of SEQ ID NO: 36. The anti-GASP-1 scFv may comprise the amino acid sequence of SEQ ID NO: 43. The anti-GASP-1 scFv may consist of the amino acid sequence of SEQ ID NO: 43.

[0085] The CAR may further comprise a signal peptide (SEQ ID NO: 35), a CD8 hinge (SEQ ID NO: 37), a CD28 transmembrane intracellular domain (SEQ ID NO: 38), a CD3 zeta (SEQ ID NO: 39), T2A (SEQ ID NO: 36) and EGFRt (SEQ ID NO: 41). Elements such as interleukins, chemokines, immune checkpoint inhibitors, may enhance the efficacy of the CAR-T if they are co-expressed. Using interleukin-12 (IL-12) as an example, the CAR sequence can be CAR-T2A-EGFRt-T2A-IL-12, CAR-T2A-EGFRt-IRES-IL-12 or CAR-T2A-EGFRt-T2A-PGK promoter-IL-12. The co-stimulatory domains can be 4-1BB, OX40, etc. these elements may improve the CAR-T treatment as well. The co-stimulatory domains (4-1BB, OX40, etc.) can be added to the co-stimulatory domain of the CAR, including the following examples:

[0086] (a) a CD8 hinge, a CD28 transmembrane, 4-1BB intracellular domain, a CD3 zeta;

[0087] (b) a CD8 hinge, a CD8 transmembrane, 4-1BB intracellular domain, a CD3 zeta;

[0088] (c) a CD8 hinge, a CD28 transmembrane, OX40 intracellular domain, a CD3 zeta;

[0089] (d) a CD8 hinge, a CD8 transmembrane, OX40 intracellular domain, a CD3 zeta; and

[0090] (e) a CD8 hinge, a CD28 transmembrane intracellular domain, 4-1BB or OX40, a CD3 zeta.

[0091] In view that the currently available CAR-T therapies are rather ineffective against solid tumors, GASP-1 CAR-T therapy may be combined with currently approved CAR-T treatments such as tisagenlecleucel (Kymriah) or axicabtagene ciloleucel (Yescarta), which go after cells producing CD19, to improve effectiveness of such CAR-T treatments. GASP-1 CAR-T containing an additional CAR sequence directed against CD19 or another cancer surface antigen may also be used. A combination of GASP-1 CAR-T with another immunotherapy called a checkpoint inhibitor is also suggested. The checkpoint inhibitor may be Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab or Cemiplimab.

[0092] A method for producing an anti-GASP-1 antibody is provided. The antibody production method comprises immunizing a host with a GASP-1 peptide as an immunogen. The GASP-1 peptide may be any peptide derived from GASP-1. The GASP-1 peptide may comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-26. The GASP-1 peptide may consist of an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-26. The GASP-1 peptide may comprise the amino acid sequence of SEQ ID NO: 23. The GASP-1 peptide may consist of the amino acid sequence of SEQ ID NO: 23. The GASP-1 peptide may comprise the amino acid sequence of SEQ ID NO: 24. The GASP-1 peptide may consist of the amino acid sequence of SEQ ID NO: 24. The GASP-1 peptide may comprise the amino acid sequence of SEQ ID NO: 25. The GASP-1 peptide may consist of the amino acid sequence of SEQ ID NO: 25. The GASP-1 peptide may comprise the amino acid sequence of SEQ ID NO: 26. The GASP-1 peptide may consist of the amino acid sequence of SEQ ID NO: 26.

[0093] A method for producing a bi-specific binding protein. The bi-specific binding protein production method comprises combining the binding protein of the present invention with an additional humanized antibody to produce a bi-specific binding protein. The bi-specific binding protein may have better immunotherapy specificity and/or efficacy than the additional humanized antibody. The binding protein may be a GASP-1 antibody or CAR of the present invention. The additional humanized antibody may be selected from the group consisting of Rituximab, Alemtuzumab, Adalimumab, Efalizumab, Cetuximab, Bevacizumab, Natalizumab, Panitumumab, Ranibizumab, Ipilimumab, Belimumab, Obinutuzumab, Pertuzumab, Vedolizumab, Ramucirumab, Evolocumab, Pembrolizumab, Nivolumab, Atezolizumab, Reslizumab, Necitumumab, Trastuzumab, Pertuzumab, Ofatumumab, Durvalumab, Bortezomib, Elotuzumab, Avelumab, Cemiplimab, and Olaratumab.

[0094] For each bi-specific binding protein production method, the produced bi-specific binding protein is provided. The bi-specific binding protein comprises a binding protein of the present invention and an additional humanized antibody. The bi-specific binding protein may have better immunotherapy specificity and/or efficacy than the additional humanized antibody. The binding protein may be a GASP-1 antibody or CAR of the present invention. The additional humanized antibody may be selected from the group consisting of Rituximab, Alemtuzumab, Adalimumab, Efalizumab, Cetuximab, Bevacizumab, Natalizumab, Panitumumab, Ranibizumab, Ipilimumab, Belimumab, Obinutuzumab, Pertuzumab, Vedolizumab, Ramucirumab, Evolocumab, Pembrolizumab, Nivolumab, Atezolizumab, Reslizumab, Necitumumab, Trastuzumab, Pertuzumab, Ofatumumab, Durvalumab, Bortezomib, Elotuzumab, Avelumab, Cemiplimab, and Olaratumab.

[0095] For each binding protein or bi-specific binding protein of the present invention, a pharmaceutical composition is provided. The pharmaceutical composition comprises the binding protein or the bi-specific binding protein of the present invention, and a pharmaceutically acceptable carrier.

[0096] A method for treating a GASP-1-mediated disease or disorder in a subject in need thereof is provided. The treatment method comprises administering an effective amount of the pharmaceutical composition of the present invention to the subject.

[0097] According to the treatment method, the GASP-1-mediated disease or disorder may be a tumor. The tumor may be a solid tumor. The tumor may be a hematological tumor.

[0098] According to the treatment method, the GASP-1-mediated disease or disorder may be cancer. The subject may have received a treatment of the cancer. The GASP-1 may be expressed in granules in cells of the subject. The GASP-1 granules may be in the cytosol or on the surface of the cells. In one embodiment, the GASP-1 granules may be in the cytosol of the cells. In another embodiment, the GASP-1 granules may be on the surface of the cells. In another embodiment, the GASP-1 granules may not be in the nuclei of the cells.

[0099] The treatment method may further comprise determining the average number, and/or the average diameter, and/or the stability of the GASP-1 granules in the cells of the subject before a cancer treatment. The treatment method may further comprise determining the average number, the average diameter, and/or the stability of the GASP-1 granules in the cells of the subject after the cancer treatment, and optionally comparing the average number, the average diameter, and/or the stability of the GASP-1 granules in the cells of the subject before the cancer treatment with that after the cancer treatment.

[0100] According to the treatment method, the cancer may be selected from the group consisting of bladder cancer, breast cancer, colon cancer, endometrial carcinoma, esophagus squamous cell carcinoma, glioma, head cancer, hepatocellular carcinoma, infiltrating ductal breast carcinoma, larynx cancer, lung cancer, melanoma, mucinous cystadenocarcinoma of ovary, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small bowel malignant stromal tumor and stomach adenocarcinoma. The cancer may be selected from the group consisting of bladder cancer, breast cancer, colon cancer, glioblastoma, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer and prostate cancer. The breast cancer may be high grade ductal carcinoma in situ (DCIS) breast cancer or triple negative breast cancer. The lung cancer may be non-small cell lung cancer (NSCLC).

[0101] A method for inhibiting growth of cells expressing GASP-1 is provided. The inhibition method comprises administering an effective amount of the pharmaceutical composition of the present invention to the cells. The cells may be cancer cells. The cells may be in a patient having cancer. The cancer may be selected from the group consisting of bladder cancer, breast cancer, colon cancer, endometrial carcinoma, esophagus squamous cell carcinoma, glioma, head cancer, hepatocellular carcinoma, infiltrating ductal breast carcinoma, larynx cancer, lung cancer, melanoma, mucinous cystadenocarcinoma of ovary, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small bowel malignant stromal tumor and stomach adenocarcinoma. The cancer may be selected from the group consisting of bladder cancer, breast cancer, colon cancer, glioblastoma, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer and prostate cancer. The breast cancer may be high grade ductal carcinoma in situ (DCIS) breast cancer or triple negative breast cancer. The lung cancer may be non-small cell lung cancer (NSCLC).

[0102] A method for inactivating exosomes, microvesicles, or oncosomes expressing GASP-1 provided. The inactivation method comprises administering an effective amount of the pharmaceutical composition of the present invention to the exosomes, microvesicles, or oncosomes. The inactivation of the exosomes, microvesicles, or oncosomes may be evidenced by a decrease in the number of surface biomarkers such as CD63, CD9 or CD81 for exosomes; CD45, CD47 for microvesicles; and heat shock proteins HSPA5 and HSPA9 for oncosomes. The exosomes, microvesicles, or oncosomes may be in a subject having cancer.

[0103] The exosomes, microvesicles, or oncosomes may be in blood circulation of the subject. The cancer may be selected from the group consisting of bladder cancer, breast cancer, colon cancer, endometrial carcinoma, esophagus squamous cell carcinoma, glioma, head cancer, hepatocellular carcinoma, infiltrating ductal breast carcinoma, larynx cancer, lung cancer, melanoma, mucinous cystadenocarcinoma of ovary, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small bowel malignant stromal tumor and stomach adenocarcinoma. The cancer may be selected from the group consisting of bladder cancer, breast cancer, colon cancer, glioblastoma, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer and prostate cancer. The breast cancer may be high grade ductal carcinoma in situ (DCIS) breast cancer or triple negative breast cancer. The lung cancer may be non-small cell lung cancer (NSCLC).

Example 1. Identification of GASP-1 Oncosomes or Microvesicles in Prostate Cancer

[0104] GASP-1 expression in prostate cancer cells was examined using a polyclonal antibody against EEASPEAVAGVGFESK (SEQ ID NO: 22). GASP-1 oncosomes or microvesicles were released by budding from cell membrane. As shown in FIG. 1, while normal prostate cells do not release GASP-1 oncosomes or microvesicles (left panel), GASP-1 oncosomes can be seen budding from cell membrane via forming membrane blebs protruding from cancer cell membrane before being released (see arrows in right panel). The oncosomes or microvesicles appeared to originate from GASP-1 initially concentrated in certain regions of the cancer cell membrane. Completely released oncosomes or microvesicles can also be seen near the area of release (right panel).

Example 2. Presence of GASP-1 Granules of Various Sizes in Cancer Cells

[0105] GASP-1 expression in various cancer cells was examined using a polyclonal antibody against EEASPEAVAGVGFESK (SEQ ID NO: 22). Unlike the released extracellular GASP-1 oncosomes described in Example 1 above, granules expressing GASP-1 were found in the cytosol or on the surface of cancer cells including breast, triple negative breast, prostate, lung, liver, ovarian, glioblastoma, gastric, bladder, melanoma or colon cancer. Because GASP-1 overexpression is required for cancer initiation and progression, the production of GASP-1 granules may be a required step for cancer progression.

[0106] FIG. 2 shows immunohistochemistry (IHC) staining of High Grade DCIS Breast Cancer using the polyclonal antibody against EEASPEAVAGVGFESK (SEQ ID NO: 22). In normal breast cells, GASP-1 is only expressed in some nuclei and not in the cytosol (FIG. 2 left panel). In cancer cells, the GASP-1 granules were associated with cell membrane, in the cytosol, clustered around the nuclear membrane and inside the nucleus (FIG. 2 right panel and FIG. 3).

[0107] The GASP-1 granules could originate from endosomes. However, unlike endosomes which have a diameter of 0.5 ?m when matured, GASP-1 granules of varying sizes ranging from powdery granules, fine granules, to coarse granules are present in this cancer (FIG. 3). The coarse GASP-1 granules with diameter of 1.0 to 5.0 ?m may be bigger than the endosomes. Furthermore, unlike the extracellular GASP-1 oncosomes described in FIG. 1, the coarse GASP-1 granules are still attached to the cell membrane (see arrows in FIG. 3) and are not released from the cell membrane. GASP-1 granules also do not form membrane blebs protruding from cell membrane that are the hallmark of oncosomes. The coarse GASP-1 granules are likely formed by either maturation of smaller granules or by aggregation of smaller granules. It is possible that association of so many coarse GASP-1 granules on cell membrane may cause destabilization of the membrane and breaking up (or fragmentation) of cell membranes. The fragmented cell membrane pieces still contain many GASP-1 granules attached to them (FIG. 3). One consequence of breaking up cell membrane would be the release of many GASP-1 granules originally present inside the cell (in the cytosol, clustered on nuclear membrane, or in the nucleus) into tumor microenvironment and later released into blood circulation. We have also found that as cancer becomes more severe, the size of GASP-1 granules becomes bigger and coarse.

[0108] The presence of GASP-1 granules on cancer cell surface and absence on normal cell surface offers the opportunity to specifically targeting cancer cells and spare normal cells. The abundant presence of coarse GASP-1 granules on cancer cell surface could also make GASP-1-targeted cancer treatment more effective. In a solid tumor like DCIS breast cancer and other cancers, GASP-1 granules were also found on the surfaces of different cell layers. This would also make immunotherapy targeting GASP-1 granules rather effective because they would be accessible to cancer-treating agents.

[0109] Triple Negative Breast Cancer, which is a very aggressive form of breast cancer, shows almost identical GASP-1 granular pattern as high grade DCIS (FIG. 4). Again, GASP-1 granules of varying sizes ranging from powdery granules, fine granules, to coarse granules are present in this cancer. The arrows point to GASP-1 granules still attached to cell membrane or membrane fragments.

[0110] Lung cancer is among the most deadly cancers for both men and women. Its death rate exceeds that of the three most common cancers (colon, breast, and pancreatic) combined. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases and most of newly diagnosed lung cancer patients are late stage. Early detection is very important and with availability of biopsy sample, the presence and abundance of GASP-1 granules in the cytosol could represent early detection. FIG. 5 shows a representative IHC staining of NSCLC. While in normal lung cells, GASP-1 granules are only present in some nuclei and not in the cytosol (left panel), GASP-1 granules of various sizes are present in the cytosol, or attached to the cell membrane in NSCLC (right panel). Arrows in the right panel point out the association of GASP-1 granules with cell membrane and membrane fragments. Therefore, IHC staining of lung tissues for GASP-1 granules from individuals suspecting of lung cancer would confirm the presence of lung cancer.

[0111] FIG. 6 shows GASP-1 granules in glioblastoma cells. While GASP-1 granules were absent from normal brain cells (left panel), there were highly abundant in glioblastoma cells (right panel). GASP-1 granules of various sizes are present in the cytosol and on the surface of the glioblastoma cells.

[0112] Similar large amounts of GASP-1 granules were found to be present in the cytosol or on the surface of ovarian, colon, melanoma, gastric and prostate cancer cells.

[0113] The presence of so many GASP-1 granules of varying sizes inside the cancer cell is unexpected. GASP-1 granules are present on all cancer cell surfaces we studied; it can be assumed that they will also be present in other cancer cell surfaces such as endometrial carcinoma, esophagus squamous cell carcinoma, larynx cancer, mucinous cystadenocarcinoma of ovary, renal cell carcinoma, small bowel malignant stromal tumor, and stomach adenocarcinoma. Thus, GASP-1 is a universal cancer biomarker and GASP-1 granule production may represent a required step in cancer progression. One can therefore use the presence of GASP-1 granules, their subcellular localization, their abundance, etc., to assess cancer and cancer severity.

Example 3. GASP-1 scFv Sequences

[0114] A monoclonal antibody was produced against GASP-1 peptide fragment EEASPEAVAGVGFESK (SEQ ID NO: 22). Several clones were isolated. Clone 14B8 showed the highest titer against the GASP-1 peptide. Cell lysates from clone 14B8 were stored in a TriZol solution. cDNA was reversely transcribed from the total RNA in the cell lysates followed by PCR amplification of the variable regions (both heavy chain (VH) and light chains) of the antibody. FIG. 7 shows the gel analysis of PCR products using VL specific primers (lane 1) or VH specific primers (lane 2). The resulting PCR fragments were then cloned into a standard cloning vector separately and sequenced. Using PCR, the heavy and light chains of clone 14B8 were sequenced, and two variable light chain sequences were found.

[0115] Table 1 shows the various amino acid sequences and nucleotide sequences of clone 14B88, for example, the variable heavy (VH) chain, including its first, second and third complementarity-determining regions (VHCDR1, VHCDR2 and VHCDR3), the first variable light (VL1) chain, including its first, second and third complementarity-determining regions (VL1CDR1, VL1CDR2 and VL1CDR3), and the second variable light (VL2) chain, including its first, second and third complementarity-determining regions (VL2CDR1, VL2CDR2 and VL2CDR3). The two light chain sequences differ in only one amino acid in CDR1 (comparing SEQ ID NOs: 9 and 17). The change from N to Y is due to codon change from TAT to AAT as described in SEQ ID: NOs: 13 and 19. This discrepancy might be due to multiple coloniality of the target subclone. The change in the nucleotide and amino acid is highlighted in bold and underlined.

TABLE-US-00001 TABLE1 Sequencesofclone14B8 SEQID No. Name Sequence NO 1 VH EVKLVESGPGLVAPSQSLTITCTVSGFSLTGYGVNWVRQPPGK 1 GLEWLGMIWHNGSTDYNSALRSRLSINKDKSKNQVFLKMNSL QTDDTARYYCARGGRSPWFPYWGQGTLVTVSA 2 VHCDR1 GFSLTGY 2 3 VHCDR2 WHNGS 3 4 VHCDR3 GGRSPWFPY 4 5 VH GAGGTGAAGTTGGTGGAGTCAGGACCTGGCCTGGTGGCGC 5 CCTCACAGAGCCTGACCATCACATGCACCGTCTCAGGGTTC TCATTAACCGGCTATGGTGTAAACTGGGTTCGCCAGCCTCCA GGAAAGGGTCTGGAGTGGCTGGGAATGATCTGGCATAATG GAAGCACAGACTATAATTCAGCTCTCAGATCCAGACTGAGCA TCAACAAGGACAAGTCCAAGAACCAAGTTTTCTTAAAAATGA ACAGTCTGCAAACTGATGACACAGCCAGGTACTACTGTGCC AGAGGGGGAAGGTCCCCCTGGTTTCCTTACTGGGGCCAAG GGACTCTGGTCACTGTCTCTGCA 6 VHCDR1 GGGTTCTCATTAACCGGCTAT 6 7 VHCDR2 TGGCATAATGGAAGC 7 8 VHCDR3 GGGGGAAGGTCCCCCTGGTTTCCTTAC 8 9 VL1 DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTNLNWLLQ 9 RPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAD DLGVYYCWQGTHFPWTFGGGTKLEIK 10 VL1CDR1 KSSQSLLDSDGKTNLN 10 11 VL1CDR2 LVSKLDS 11 12 VL1CDR3 WQGTHFPWT 12 13 VL1 GATGTTGTGATGACCCAGACTCCACTCACTTTGTCGGTTACC 13 ATTGGACAACCAGCCTCCATCTCTTGCAAGTCAAGTCAGAGC CTCTTAGATAGTGATGGAAAGACATATTTGAATTGGTTGTTA CAGAGGCCAGGCCAGTCTCCAAAGCGCCTAATCTATCTGGT GTCTAAACTGGACTCTGGAGTCCCTGACAGGTTCACTGGCA GTGGATCAGGGACAGATTTCACACTGAAAATCAGCAGAGTG GAGGCTGACGATTTGGGAGTTTATTATTGCTGGCAAGGTAC ACATTTTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAA TCAAA 14 VL1CDR1 AAGTCAAGTCAGAGCCTCTTAGATAGTGATGGAAAGACATAT 14 TTGAAT 15 VL1CDR2 CTGGTGTCTAAACTGGACTCT 15 16 VL1CDR3 TGGCAAGGTACACATTTTCCGTGGACG 16 17 VL2 DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQ 17 RPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAD DLGVYYCWQGTHFPWTFGGGTKLEIK 18 VL2CDR1 KSSQSLLDSDGKTYLN 18 19 VL2CDR2 LVSKLDS 11 20 VL2CDR3 WQGTHFPWT 12 21 VL2 GATGTTGTGATGACCCAGACTCCACTCACTTTGTCGGTTACC 19 ATTGGACAACCAGCCTCCATCTCTTGCAAGTCAAGTCAGAGC CTCTTAGATAGTGATGGAAAGACAAATTTGAATTGGTTGTTA CAGAGGCCAGGCCAGTCTCCAAAGCGCCTAATCTATCTGGT GTCTAAACTGGACTCTGGAGTCCCTGACAGGTTCACTGGCA GTGGATCAGGGACAGATTTCACACTGAAAATCAGCAGAGTG GAGGCTGACGATTTGGGAGTTTATTATTGCTGGCAAGGTAC ACATTTTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAA TCAAA 22 VL2CDR1 AAGTCAAGTCAGAGCCTCTTAGATAGTGATGGAAAGACAAA 20 TTTGAAT 23 VL2CDR2 CTGGTGTCTAAACTGGACTCT 15 24 VL2CDR3 TGGCAAGGTACACATTTTCCGTGGACG 16 25 Linker GGGGSGGGGSGGGG 21 26 GASP-1peptide EEASPEAVAGVGFESK 22 fragment 27 GASP-1peptide WKEDEAISEATDR 23 fragment 28 GASP-1peptide CSKSSPKAEEEEV 24 fragment 29 GASP-1peptide EEASIQAGSQAVEE 25 fragment 30 GASP-1peptide FWDGKEVSEEAGPC 26 fragment

Example 4. Anti-GASP-1 scFv-Fc Proteins

[0116] Anti-GASP-1 scFv-Fc proteins were generated based on the sequences of clone 14B8. Using different variable light (VL) chain sequences, two scFv-Fc expression vectors, scFv1-Fc and scFv2-Fc, were prepared. The expression vector construct design is shown in FIG. 8. The VL of scFv1-Fc is the 1468 Light Chain #2 (SEQ ID NO: 9) while the VL of scFv2-Fc is the 1468 Light Chain #1 (SEQ ID NO: 17). The expression vectors were transiently transfected into HEK293 cells, and scFv-Fc proteins were expressed in the HEK293 cells with Gibco? FreeStyle? 293 Expression Medium.

[0117] scFv-Fc proteins were purified by Protein A affinity chromatography and their affinity for target PC-3 cancer cells were analyzed. In flow cytometric analyses (FACS), 5?10.sup.5 PC-3 cells were stained with either scFv1-Fc or scFv2-Fc protein, followed by PE-anti-Human IgG Fc antibody as the secondary antibody. FIG. 9 shows that 49.4% of the PC-3 cells were recognized by the scFv1-Fc protein while only 8.39% of the PC-3 cells were recognized by the scFv2-Fc protein, indicating that scFv1 has a significant higher affinity for PC-3 cells.

Example 5. GASP-1 Expression on Cancer Cell Surface

[0118] Expression of GASP-1 in various cancer cells were studied using an anti-GASP-1 monoclonal antibody against EEASPEAVAGVGFESK (SEQ ID NO: 22). GASP-1 was found on the surface of lung and ovarian cancer cells (FIG. 10). The appearance of GASP-1 on lung cancer surface confirms the result of immunohistochemical (IHC) analysis (FIG. 5) which shows the presence of GASP-1 granules on cancer cell surface. GASP-1 were also found on the surfaces of other cancer cells examined, for example, colon, breast, leukemia, melanoma, glioblastoma and pancreatic cancer cells by flow cytometric analysis. Based on these results, GASP-1 may be a universal cancer biomarker and appears on cell surfaces of other cancers including endometrial carcinoma, esophagus squamous cell carcinoma, glioma, hepatocellular carcinoma, infiltrating ductal breast carcinoma, larynx cancer, renal cell carcinoma, small bowel malignant stromal tumor, and stomach adenocarcinoma. The rather stable association of GASP-1 granules with cell membranes of many cancers would make GASP-1 granules a good target for both CAR-T and humanized recombinant antibodies for treating cancers including many solid tumors.

Example 6. Construction of CAR Vector

[0119] Because GASP-1 granules are present on the surfaces of different cancer cell layers (see FIG. 3 and FIG. 4), not buried inside cell layers, and are not on normal cell surfaces, a full length of chimeric antigen receptor (CAR) was synthesized with scFv1 and subcloned into lentivirus vector (FIG. 11). The insert was confirmed by Sanger sequencing.

[0120] Table 2 shows the nucleotide and amino acid sequences used for the production of CAR cassette. A CAR construct was prepared using nucleotide sequences for the Lenti-EF-1alpha promoter (SEQ ID NO: 27), a signal peptide (SEQ ID NO: 28), scFv1 (SEQ ID NO: 29), CD28 hinge (SEQ ID NO: 30), CD28 intramembrane sequence (SEQ ID NO: 31), CD3z (SEQ ID NO: 32), T2A (thosea asigna virus 2A self-cleaving peptide) (SEQ ID NO: 33) and EGFRt (truncated human epidermal growth factor receptor polypeptide) (SEQ ID NO: 34). The GASP-1 CAR construct comprises amino acid sequences for signal sequence (SEQ ID NO: 35), scFv1 (SEQ ID NO: 36) or scFv2 (SEQ ID NO: 43), CD28 hinge (SEQ ID NO: 37), CD28 transmembrane sequence (SEQ ID NO: 38), CD3z (SEQ ID NO: 39), T2A (SEQ ID NO: 40), and EGFRt (SEQ ID NO: 41). scFv1 may be substituted with scFv2 (SEQ ID NO: 42).

TABLE-US-00002 TABLE2 SequencesofCARconstruct SEQID No. Name Sequence NO 31 EF-1alpha GAGTAATTCATACAAAAGGACTCGCCCCTGCCTTGGGGAA 27 promoter TCCCAGGGACCGTCGTTAAACTCCCACTAACGTAGAACCC AGAGATCGCTGCGTTCCCGCCCCCTCACCCGCCCGCTCTC GTCATCACTGAGGTGGAGAAGAGCATGCGTGAGGCTCCG GTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCC CCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTG CCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATG TCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGA ACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTC GCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGT GTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCC TTGCGTGCCTTGAATTACTTCCACGCCCCTGGCTGCAGTA CGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGG GAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTC GTGCTTGAGTTGAGGCCTGGCTTGGGCGCTGGGGCCGCC GCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGC TTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTG CTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCG GGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCG CGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTT CGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATC GGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTG CCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCG GCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAA AGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAAT GGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCA CCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCG CTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGC ACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTA GGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCAC ACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCAC TTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGG ATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTT TTTTTCTTCCATTTCAGGTGTCGTGA 32 Signalpeptide ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCT 28 TGCTGCTCCACGCCGCCAGGCCG 33 scFv1 GATGTTGTGATGACCCAGACTCCACTCACTTTGTCGGTTAC 29 CATTGGACAACCAGCCTCCATCTCTTGCAAGTCAAGTCAG AGCCTCTTAGATAGTGATGGAAAGACATATTTGAATTGGT TGTTACAGAGGCCAGGCCAGTCTCCAAAGCGCCTAATCTA TCTGGTGTCTAAACTGGACTCTGGAGTCCCTGACAGGTTC ACTGGCAGTGGATCAGGGACAGATTTCACACTGAAAATCA GCAGAGTGGAGGCTGACGATTTGGGAGTTTATTATTGCTG GCAAGGTACACATTTTCCGTGGACGTTCGGTGGAGGCACC AAGCTGGAAATCAAAGGTGGAGGTGGCAGCGGAGGAGGT GGGTCCGGCGGTGGAGGAAGCGAGGTGAAGTTGGTGGA GTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGAC CATCACATGCACCGTCTCAGGGTTCTCATTAACCGGCTAT GGTGTAAACTGGGTTCGCCAGCCTCCAGGAAAGGGTCTG GAGTGGCTGGGAATGATCTGGCATAATGGAAGCACAGAC TATAATTCAGCTCTCAGATCCAGACTGAGCATCAACAAGG ACAAGTCCAAGAACCAAGTTTTCTTAAAAATGAACAGTCTG CAAACTGATGACACAGCCAGGTACTACTGTGCCAGAGGG GGAAGGTCCCCCTGGTTTCCTTACTGGGGCCAAGGGACTC TGGTCACTGTCTCTGCAAGATCT 34 CD8hinge CCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCA 30 CCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGT GCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGG CTGGACTTCGCCTGTGATA 35 CD28 TTCTGGGTGCTGGTCGTTGTGGGCGGCGTGCTGGCCTGC 31 Transmembrane TACAGCCTGCTGGTGACAGTGGCCTTCATCATTTTTGGG intracellular TGAGGAGCAAGCGGAGCAGACTGCTGCACAGCGACTACA TGAACATGACCCCCCGGAGGCCTGGCCCCACCCGGAAGC ACTACCAGCCCTACGCCCCTCCCAGGGATTTCGCCGCCTA CCGGAGC 36 CD3zeta AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTAC 32 AAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAG GACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTG GCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAG AACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATA AGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCG AGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGG GTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCA CATGCAGGCCCTGCCCCCTCGC 37 T2A GAGGGCAGAGGCAGCCTGCTGACATGTGGCGACGTGGAA 33 GAGAACCCTGGCCCC 38 EGFRt ATGTGGCTGCAGAGCCTGCTGCTCTTGGGCACTGTGGCCT 34 GCAGCATCTCTCGCAAAGTGTGTAACGGAATAGGTATTGG TGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTA AACACTTCAAAAACTGCACCTCCATCAGTGGCGATCTCCAC ATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATA CTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAAC CGTAAAGGAAATCACAGGGTTTTTGCTGATTCAGGCTTGG CCTGAAAACAGGACGGACCTCCATGCCTTTGAGAACCTAG AAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTC TCTTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTAC GCTCCCTCAAGGAGATAAGTGATGGAGATGTGATAATTTC AGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGA AAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTAT AAGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCA GGTCTGCCATGCCTTGTGCTCCCCCGAGGGCTGCTGGGG CCCGGAGCCCAGGGACTGCGTCTCTTGCCGGAATGTCAG CCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGA GGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCAT ACAGTGCCACCCAGAGTGCCTGCCTCAGGCCATGAACATC ACCTGCACAGGACGGGGACCAGACAACTGTATCCAGTGT GCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCC CGGCAGGAGTCATGGGAGAAAACAACACCCTGGTCTGGA AGTACGCAGACGCCGGCCATGTGTGCCACCTGTGCCATCC AAACTGCACCTACGGATGCACTGGGCCAGGTC1IGAAGGC TGTCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTG GGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTGGCCC TGGGGATCGGCCTCTTCATG 39 Signalpeptide MALPVTALLLPLALLLHAARP 35 40 scFv1 DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTNLNWL 36 LQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRV EADDLGVYYCWQGTHFPWTFGGGTKLEIKGGGGSGGGGS GGGGSEVKLVESGPGLVAPSQSLTITCTVSGFSLTGYGVNW VRQPPGKGLEWLGMIWHNGSTDYNSALRSRLSINKDKSKN QVFLKMNSLQTDDTARYYCARGGRSPWFPYWGQGTLVTVS A 41 CD8hinge TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFA 37 C 42 CD28 FWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMN 38 Transmembrane MTPRRPGPTRKHYQPYAPPRDFAAYRS intracellular 43 CD3zeta RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGR 39 DPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERR RGKGHDGLYQGLSTATKDTYDALHMQALPPR 44 T2A EGRGSLLTCGDVEENPGP 40 45 EGFRt MWLQSLLLLGTVACSISRKVCNGIGIGEFKDSLSINATNIKH 41 FKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEI TGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSL NITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSG QKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSC RNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAM NITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVW KYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATG MVGALLLLLVVALGIGLFM 46 scFv2 GATGTTGTGATGACCCAGACTCCACTCACTTTGTCGGTTAC 42 CATTGGACAACCAGCCTCCATCTCTTGCAAGTCAAGTCAG AGCCTCTTAGATAGTGATGGAAAGACAAATTTGAATTGGT TGTTACAGAGGCCAGGCCAGTCTCCAAAGCGCCTAATCTA TCTGGTGTCTAAACTGGACTCTGGAGTCCCTGACAGGTTC ACTGGCAGTGGATCAGGGACAGATTTCACACTGAAAATCA GCAGAGTGGAGGCTGACGATTTGGGAGTTTATTATTGCTG GCAAGGTACACATTTTCCGTGGACGTTCGGTGGAGGCACC AAGCTGGAAATCAAAGGTGGAGGTGGCAGCGGAGGAGGT GGGTCCGGCGGTGGAGGAAGCGAGGTGAAGTTGGTGGA GTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGAC CATCACATGCACCGTCTCAGGGTTCTCATTAACCGGCTAT GGTGTAAACTGGGTTCGCCAGCCTCCAGGAAAGGGTCTG GAGTGGCTGGGAATGATCTGGCATAATGGAAGCACAGAC TATAATTCAGCTCTCAGATCCAGACTGAGCATCAACAAGG ACAAGTCCAAGAACCAAGTTTTCTTAAAAATGAACAGTCTG CAAACTGATGACACAGCCAGGTACTACTGTGCCAGAGGG GGAAGGTCCCCCTGGTTTCCTTACTGGGGCCAAGGGACTC TGGTCACTGTCTCTGCAAGATCT 47 scFv2 DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLL 43 QRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVE ADDLGVYYCWQGTHFPWTFGGGTKLEIKGGGGSGGGGSG GGGSEVKLVESGPGLVAPSQSLTITCTVSGFSLTGYGVNWV RQPPGKGLEWLGMIWHNGSTDYNSALRSRLSINKDKSKNQ VFLKMNSLQTDDTARYYCARGGRSPWFPYWGQGTLVTVSA

[0121] Using GASP-1 granules as a CAR-T target, CAR-T therapy targeting cancer cell surface GASP-1 granules represents a new approach and would be effective against both hematologic and solid tumors.

Example 7. CAR-T Cells

[0122] To assess CAR-T percentage, CAR-T cells were stained with Anti-EGFR and PE-conjugated Anti-human IgG. Flow cytometer analysis showed that 34.9% cells were CAR-positive (FIG. 12).

[0123] To test the effectiveness of CAR-T, the CAR-T cells were co-cultured with target cell lines PC-3 at different E/T ratio for 24 hours, the supernatant was harvested for determination of cytokine release. The data showed that IL-2 and IFN-? secreted by CAR-T cells were increased after being engaged with target tumor cells (FIG. 13).

Example 8. Construction of Humanized Antibodies Containing Anti-GASP-1 scFv Sequences

[0124] A humanized antibody containing the scFv1 sequence was prepared. A first antibody may comprise amino acid sequences for a heavy chain (SEQ ID NO: 44), including a variable region VH (SEQ ID NO: 1) and a human constant region (SEQ ID NO: 45), and a light chain (SEQ ID: 46), including variable region VL1 (SEQ ID NO: 9) joined by a human constant region (SEQ ID NO: 47). A second antibody may comprise amino acid sequences for a heavy chain (SEQ ID NO: 44), including variable region VH (SEQ ID NO: 1) and a human constant region (SEQ ID NO: 45), and a light chain (SEQ ID: 48), including variable region VL2 (SEQ ID NO: 17) joined by a human constant region (SEQ ID NO: 47). Table 3 shows the various sequences used to make the anti-GASP-1 humanized antibodies. The designed chimeric antibody chains were synthesized and subcloned into the mammalian expression vector and were transiently transfected into HEK293 cells. The mAb was purified by Protein A affinity chromatography and SEC-HPLC. After ultrafiltration, the final product was subjected to 0.2-micron sterile filtration. The purity of the protein is >99% and the endotoxin is lower than 1 EU/mg.

TABLE-US-00003 TABLE3 Humanizedanti-GASP-1antibodysequences SEQID No. Name Sequence NO 48 HeavyChain EVKLVESGPGLVAPSQSLTITCTVSGFSLTGYGVNWVRQPPGKG 44 LEWLGMIWHNGSTDYNSALRSRLSINKDKSKNQVFLKMNSLQT DDTARYYCARGGRSPWFPYWGQGTLVTVSAASTKGPSVFPLAPS SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK 49 Human ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG 45 constant ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP HeavyChain SNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM HEALHNHYTQKSLSLSPGK 50 LightChain1 DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTNLNWLLQR 46 PGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEADDLG VYYCWQGTHFPWTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGT ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 51 Human RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN 47 constant ALQSGNSQESVTEQDSKDSTYSLSSILTLSKADYEKHKVYACEV LightChain THQGLSSPVTKSFNRGEC 52 LightChain2 DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRP 48 GQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEADDLGV YYCWQGTHFPWTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTA SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0125] Although the invention is illustrated and described herein with reference to specific embodiments, the invention is not intended to be limited to the details shown. Rather, various modifications may be made in the details within the scope and range of equivalents of the claims without departing from the invention.